Abdulla A. Damluji, MD, PhD Profile picture
Nov 5, 2021 20 tweets 18 min read Read on X
Cardiac Arrest and Cardiogenic Shock

There is a societal paper on this in the works too!

Very important work!

@Babar_Basir @venumenon10

#TCT2021 @TCTMD
Methylprednisone - ? not helpful

Advanced reperfusion strategies - small trial

#TCT2021
SCAI Shock Classification

Milrinone vs Dobutamine - no difference

Gaps in pressers in CICU setting: pressers and antiplatelets

@seanvandiepen @JasonKatzMD

#TCT2021
Invasive hemodynamics monitoring

MCS

Unloading

#TCT2021
Shock Teams - CICU @JACCJournals

3-axis model

HF readmission in shock pt

Excellent @Babar_Basir

#TCT2021

@SandeepNathanMD excellent session
***Multi-vessel PCI in Shock***

First side of the coin

Multivessel PCI should not be performed in shock ??

Culprit Shock: Culprit only

NNT = 12

@thiele_holger

#TCT2021
European guidelines

Long term outcomes

STEM pts?
Culprit lesion only PCI and followed by stage PCI in shock
Multivessel PCI in Shock is Way to Go

ESC Guidelines

CI cross in culprit cross at one year?

Metaanalysis - may be there is benefit?

But there is increased risk in renal failure

Culprit is open label - procedural differences?

@BillONeillMD

#TCT2021
NCSI -

77% improved outcomes with support

Culprit vs NCSI

#TCT2021
Conclusion - too nuanced to tell?

#TCT2021
Decisions to use what device in cardiogenic shock

@SandeepNathanMD
Trials and registry data

Impella vs balloon pump
Impella CP in AMI Shock?

#TCT2021
The Pro Case?

Impella CP as first line in shock

Goal in AMI Shock - improved supply/demand

Hemodynamic Effect of IABP, pLVAD, and ECMO

#TCT2021
IABP in AMI-CS

The longer patients linger? the more likely they die...@behnam_tehrani

#TCT2021
Impella Data

Reducing cardiac work

NCSI data @Babar_Basir
Shock teams in patients from the critical care cardiology network @ShashankSinhaMD
Escalation of Device Therapies

- ECMO + Impella (facilitating LV recovery?)

All good, but we need clinical trials in this space.

So far it is hard to argue with @SandeepNathanMD
Excellent session and great speakers @BinitaShahMD @NavinKapur4

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Abdulla A. Damluji, MD, PhD

Abdulla A. Damluji, MD, PhD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @DrDamluji

Mar 31
Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism: @NEJM

🥸 - good work #ACC25 @ACCinTouch

👇👇👇 Image
🥸1️⃣ In cancer-associated VTE, extended anticoagulation is common—but the dose remains uncertain. The API-CAT trial tested reduced-dose vs. full-dose apixaban after 6 months of initial therapy.
🥸2️⃣ 1,766 patients with active cancer and prior VTE were randomized to apixaban 2.5 mg BID or 5 mg BID for 12 months. Median follow-up was nearly 12 months.
Read 21 tweets
Mar 31
Global Effect of Cardiovascular Risk Factors on Lifetime Estimates: @NEJM

🥸 Great work from Germany on global life time risk of CVD risk

😱 Summary

👇👇👇 Image
🥸1️⃣ Lifetime cardiovascular risk increases with the number of classic risk factors you carry at age 50. The Global Cardiovascular Risk Consortium analyzed over 2 million people to estimate how much risk factors shorten life and healthspan.
🥸2️⃣ Five risk factors were studied: high blood pressure, high cholesterol, diabetes, smoking, and unhealthy body weight.
Read 22 tweets
Mar 31
Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a): @NEJM #ACC25

🥸This is a great trial

😱 Let's summarize

👇👇👇 Image
🥸1️⃣ Elevated concentrations of lipoprotein(a) are a strong, independent risk factor for cardiovascular disease. Lepodisiran, a long-acting small interfering RNA, targets hepatic production of lipoprotein(a).
🥸2️⃣ In the ALPACA trial, 320 adults with baseline lipoprotein(a) ≥175 nmol/L were randomly assigned to receive lepodisiran (16 mg, 96 mg, or 400 mg) or placebo.
Read 21 tweets
Mar 1
2025 ACC/AHA/ACEP/NAEMSP/SCAI
Guideline for the Management of Patients
With Acute Coronary Syndromes: @CircAHA @JACCJournals

🥸Here are class 1 recommendations from the document; Massive effort - congratulations to the authors: @SVRaoMD

😱 Below

👇👇👇 Image
🥸1️⃣ In patients with suspected ACS, a 12-lead ECG should be acquired and interpreted within 10 minutes of first medical contact to identify patients with STEMI.
🥸2️⃣ In patients with suspected ACS in which the initial ECG is nondiagnostic of STEMI, serial ECGs to detect potential ischemic changes should be performed, especially when clinical suspicion of ACS is high, symptoms are persistent, or the clinical condition deteriorates.
Read 37 tweets
Feb 3
The Physiology of Hunger: @NEJM

🥸 So this is not in CV medicine, but:
(1) it is interesting and (2) it has implications for CV

😱 Good job @NEJM - Summary

👇👇👇 Image
🥸 1️⃣ Hunger is an ancient survival mechanism that evolved to keep humans alive in times of food scarcity.
🥸 2️⃣ Early humans were hunter-gatherers, who faced unpredictable food supplies. Their bodies adapted to store energy efficiently, to help with survival during famine.
Read 21 tweets
Jan 28
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation: @NEJM

🥸Summary

👇👇👇 Image
🥸 1️⃣ Abelacimab significantly reduced bleeding in atrial fibrillation patients compared to rivaroxaban, as reported in the AZALEA–TIMI 71 trial.
🥸 2️⃣ Monthly subcutaneous abelacimab achieved a 99% reduction in free factor XI levels at 150 mg and 97% at 90 mg.
Read 21 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(